NCT05364697View on ClinicalTrials.gov

IonMAN Trial- First in Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System

NAActive, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 30, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2029

Conditions
Coronary StenosisCoronary DiseaseNon-ST Elevated Myocardial InfarctionCardiovascular Diseases
Interventions
DEVICE

IoNIR Ridaforolimus-Eluting Coronary Stent System

The IoNIR Ridaforolimus-Eluting Coronary Stent System is a sterile single-use device/drug combination product, comprised of a cobalt chromium (CoCr) alloy-based stent coated with a bioresorbable polymer mesh which is embedded with drug, mounted on a Rapid Exchange (RX) delivery system.

Trial Locations (4)

Unknown

InCor, São Paulo

Meir Medical Center, Kfar Saba

Rabin Medical Center, Petah Tikva

Sourasky Medical Center, Tel Aviv

Sponsors

Lead Sponsor

Medinol Ltd.
All Listed Sponsors
lead

Medinol Ltd.

INDUSTRY

NCT05364697 - IonMAN Trial- First in Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System | Biotech Hunter | Biotech Hunter